{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:14:56Z","timestamp":1793999696418,"version":"4.8.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.eprac.2025.04.018","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:42:50Z","timestamp":1746060170000},"page":"938-945","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impulse Control Disorders in Patients With Hyperprolactinemia on Dopamine Agonist Therapy\u2014How Concerned Should We Be?"],"prefix":"10.1016","volume":"31","author":[{"given":"Ghazal","family":"Daftari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8867-607X","authenticated-orcid":false,"given":"Nicholas A.","family":"Tritos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.eprac.2025.04.018_bib1","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.eprac.2025.04.018_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11102-005-5079-0","article-title":"The epidemiology of prolactinomas","volume":"8","author":"Ciccarelli","year":"2005","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.018_bib3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.018_bib4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin Endocrinology"},{"issue":"5","key":"10.1016\/j.eprac.2025.04.018_bib5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocr Reviews"},{"key":"10.1016\/j.eprac.2025.04.018_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12020-015-0727-2","article-title":"Treating prolactinomas with dopamine agonists: always worth the gamble?","volume":"51","author":"Noronha","year":"2016","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.eprac.2025.04.018_bib7","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4103\/0974-1208.121400","article-title":"Hyperprolactinemia","volume":"6","author":"Majumdar","year":"2013","journal-title":"J Human Reproductive Sciences"},{"issue":"11","key":"10.1016\/j.eprac.2025.04.018_bib8","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1176\/appi.ajp.158.11.1783","article-title":"Psychiatric aspects of impulsivity","volume":"158","author":"Moeller","year":"2001","journal-title":"Am Journal Psychiatry"},{"issue":"21","key":"10.1016\/j.eprac.2025.04.018_bib9","first-page":"591","article-title":"Diagnostic and statistical manual of mental disorders","volume":"21","author":"Edition","year":"2013","journal-title":"Am Psychiatr Assoc"},{"issue":"3","key":"10.1016\/j.eprac.2025.04.018_bib10","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1210\/clinem\/dgz076","article-title":"Impulse control disorders in dopamine agonist-treated hyperprolactinemia: prevalence and risk factors","volume":"105","author":"De Sousa","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.018_bib11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11102-024-01383-2","article-title":"Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study","volume":"27","author":"Almalki","year":"2024","journal-title":"Pituitary"},{"issue":"6","key":"10.1016\/j.eprac.2025.04.018_bib12","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/cen.12375","article-title":"Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study","volume":"80","author":"Bancos","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"10.1016\/j.eprac.2025.04.018_bib13","doi-asserted-by":"crossref","first-page":"R287","DOI":"10.1530\/EJE-18-0667","article-title":"Management of endocrine disease: impulse control disorders in patients with hyperpolactinemia treated with dopamine agonists: how much should we worry?","volume":"179","author":"Barake","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.eprac.2025.04.018_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108278","article-title":"Ropinirole, a dopamine agonist with high D3 affinity, reduces proactive inhibition: a double-blind, placebo-controlled study in healthy adults","volume":"179","author":"Rawji","year":"2020","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.eprac.2025.04.018_bib15","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1162\/jocn_a_00241","article-title":"Dopamine agonists and the suppression of impulsive motor actions in Parkinson disease","volume":"24","author":"Wylie","year":"2012","journal-title":"J Cogn Neurosci"},{"issue":"5","key":"10.1016\/j.eprac.2025.04.018_bib16","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1162\/jocn.2008.20500","article-title":"Response inhibition and response selection: two sides of the same coin","volume":"20","author":"Mostofsky","year":"2008","journal-title":"J Cognitive Neuroscience"},{"issue":"3","key":"10.1016\/j.eprac.2025.04.018_bib17","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S1474-4422(17)30004-2","article-title":"Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update","volume":"16","author":"Voon","year":"2017","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.eprac.2025.04.018_bib18","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/jamainternmed.2014.5262","article-title":"Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs","volume":"174","author":"Moore","year":"2014","journal-title":"JAMA Internal Medicine"},{"issue":"4","key":"10.1016\/j.eprac.2025.04.018_bib19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1017\/S0033291705006409","article-title":"Lateralized deficit of response inhibition in early-onset schizophrenia","volume":"36","author":"Bellgrove","year":"2006","journal-title":"Psychol Medicine"},{"issue":"11","key":"10.1016\/j.eprac.2025.04.018_bib20","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1176\/appi.ajp.158.11.1884","article-title":"Deficient inhibition as a marker for familial ADHD","volume":"158","author":"Crosbie","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.eprac.2025.04.018_bib21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11065-007-9034-x","article-title":"The role of cognitive control in cocaine dependence","volume":"17","author":"Garavan","year":"2007","journal-title":"Neuropsychol Review"},{"key":"10.1016\/j.eprac.2025.04.018_bib22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40264-017-0590-6","article-title":"Dopamine agonists and impulse control disorders: a complex association","volume":"41","author":"Grall-Bronnec","year":"2018","journal-title":"Drug Safety"},{"issue":"4","key":"10.1016\/j.eprac.2025.04.018_bib23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/syn.21805","article-title":"Parkinson's disease treatment may cause impulse\u2013control disorder via dopamine D3 receptors","volume":"69","author":"Seeman","year":"2015","journal-title":"Synapse"},{"issue":"4","key":"10.1016\/j.eprac.2025.04.018_bib24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1176\/jnp.2007.19.4.473","article-title":"Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma","volume":"19","author":"Davie","year":"2007","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.018_bib25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5694\/j.1326-5377.2009.tb02289.x","article-title":"Pathological gambling and hypersexuality in cabergoline-treated prolactinoma","volume":"190","author":"Falhammar","year":"2009","journal-title":"Med Journal Aust"},{"issue":"8","key":"10.1016\/j.eprac.2025.04.018_bib26","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1055\/s-0031-1281580","article-title":"Pathological gambling induced by dopamine agonists","volume":"79","author":"Gahr","year":"2011","journal-title":"Fortschritte der Neurologie-psychiatrie"},{"key":"10.1016\/j.eprac.2025.04.018_bib27","series-title":"93rd Annual Meeting of the Endocrine Society: abstr P3-312","article-title":"Hypersexuality in cabergoline-treated prolactinoma","year":"2011"},{"issue":"4","key":"10.1016\/j.eprac.2025.04.018_bib28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.psym.2012.10.002","article-title":"Dopamine agonist-induced impulse control disorders in a patient with prolactinoma","volume":"54","author":"Almanzar","year":"2013","journal-title":"Psychosomatics"},{"issue":"5","key":"10.1016\/j.eprac.2025.04.018_bib29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/WNF.0b013e31829fc165","article-title":"Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma","volume":"36","author":"Thondam","year":"2013","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.018_bib30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7861\/clinmedicine.14-2-205","article-title":"Lesson of the month (1): cabergoline\u2013\u2018I eat funny on that\u2019","volume":"14","author":"Premaratne","year":"2014","journal-title":"Clin Medicine"},{"issue":"6","key":"10.1016\/j.eprac.2025.04.018_bib31","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/cen.13339","article-title":"Cabergoline-related impulse control disorder in an adolescent with a giant prolactinoma","volume":"86","author":"Bulwer","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.018_bib32","doi-asserted-by":"crossref","first-page":"R88","DOI":"10.1530\/EC-18-0030","article-title":"Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist","volume":"7","author":"Athanasoulia-Kaspar","year":"2018","journal-title":"Endocr Connections"},{"issue":"1134","key":"10.1016\/j.eprac.2025.04.018_bib33","first-page":"2","article-title":"Giant prolactinoma complicated by cerebrospinal fluid rhinorrhea, behavioral and neurological changes following dopamine agonist therapy: a Case Report","volume":"8","author":"Doknic","year":"2018","journal-title":"J Clin Case Rep"},{"key":"10.1016\/j.eprac.2025.04.018_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13256-019-2071-2","article-title":"Giant cabergoline-resistant prolactinoma in a man who presented with a psychotic episode during treatment: a case report","volume":"13","author":"Casulari","year":"2019","journal-title":"J Med Case Rep"},{"key":"10.1016\/j.eprac.2025.04.018_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.844718","article-title":"Binge eating and compulsive buying during cabergoline treatment for prolactinoma: a case report","volume":"13","author":"Correa e Castro","year":"2022","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.eprac.2025.04.018_bib36","article-title":"De novo psychiatric disorders in a woman with giant prolactinoma treated with cabergoline","volume":"16","author":"Belhadj Slimane","year":"2023","journal-title":"Clin Med Insights: Case Rep"},{"issue":"5","key":"10.1016\/j.eprac.2025.04.018_bib37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/WNF.0b013e3182281b2f","article-title":"Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas","volume":"34","author":"Martinkova","year":"2011","journal-title":"Clin Neuropharmacology"},{"key":"10.1016\/j.eprac.2025.04.018_bib38","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11102-013-0480-6","article-title":"Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study","volume":"17","author":"Barake","year":"2014","journal-title":"Pituitary"},{"key":"10.1016\/j.eprac.2025.04.018_bib39","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s12020-018-1744-8","article-title":"Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up","volume":"62","author":"Celik","year":"2018","journal-title":"Endocrine"},{"issue":"7","key":"10.1016\/j.eprac.2025.04.018_bib40","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1210\/jc.2018-02202","article-title":"Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study","volume":"104","author":"Dogansen","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2025.04.018_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.579606","article-title":"Depression and impulsivity self-assessment tools to identify dopamine agonist side effects in patients with pituitary adenomas","volume":"11","author":"Hinojosa-Amaya","year":"2020","journal-title":"Front Endocrinology"},{"key":"10.1016\/j.eprac.2025.04.018_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ghir.2020.101356","article-title":"Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas","volume":"55","author":"Ozkaya","year":"2020","journal-title":"Growth Horm IGF Res"},{"key":"10.1016\/j.eprac.2025.04.018_bib43","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40618-020-01478-0","article-title":"Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study","volume":"44","author":"Beccuti","year":"2021","journal-title":"J Endocrinological Invest"},{"issue":"1","key":"10.1016\/j.eprac.2025.04.018_bib44","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12902-022-01009-3","article-title":"The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study","volume":"22","author":"Ke","year":"2022","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"10.1016\/j.eprac.2025.04.018_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/WNN.0000000000000320","article-title":"Effect of dopaminergic therapy on impulse control disorders in patients with a prolactinoma","volume":"36","author":"Ozdeniz Varan","year":"2023","journal-title":"Cogn Behav Neurol"},{"issue":"1","key":"10.1016\/j.eprac.2025.04.018_bib46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4103\/0028-3886.370452","article-title":"Impulse control disorders with short-term use of cabergoline in macroprolactinomas: a prospective study with a brief review of literature","volume":"71","author":"Sanjan","year":"2023","journal-title":"Neurol India"},{"issue":"6","key":"10.1016\/j.eprac.2025.04.018_bib47","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1210\/clinem\/dgac718","article-title":"A genetic assessment of dopamine agonist-induced impulse control disorder in patients with prolactinoma","volume":"108","author":"Sahin","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2025.04.018_bib48","article-title":"Impulse control disorders in southern Iraqi patients medicated with cabergoline for prolactinoma","volume":"16","author":"Mohammad","year":"2024","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.eprac.2025.04.018_bib49","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/mdc3.13128","article-title":"Does the country make a difference in impulse control disorders? A systematic review","volume":"8","author":"Parra-D\u00edaz","year":"2021","journal-title":"Movement Disord Clin Pract"},{"issue":"5","key":"10.1016\/j.eprac.2025.04.018_bib50","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients","volume":"67","author":"Weintraub","year":"2010","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1016\/j.eprac.2025.04.018_bib51","first-page":"1089","article-title":"Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy","volume":"23","author":"Hamidianjahromi","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.eprac.2025.04.018_bib52","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1007\/s12020-016-1088-1","article-title":"Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists","volume":"55","author":"De Sousa","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.eprac.2025.04.018_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2023.102910","article-title":"Impulse control disorders in patients with pituitary tumors treated with dopamine agonists: a systematic review","volume":"54","author":"Hamblin","year":"2023","journal-title":"Arch of Med Res"},{"key":"10.1016\/j.eprac.2025.04.018_bib54","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1055\/s-0044-1787693","article-title":"Recent perspectives on impulse control disorder in dopamine agonist-treated patients in endocrine practice","volume":"7","author":"Aldahmani","year":"2024","journal-title":"J Diabetes Endocr Pract"},{"issue":"11","key":"10.1016\/j.eprac.2025.04.018_bib55","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1176\/appi.ajp.162.11.2184","article-title":"Impulse control disorders in adult psychiatric inpatients","volume":"162","author":"Grant","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.eprac.2025.04.018_bib56","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.psychres.2018.05.006","article-title":"Minnesota Impulse Disorders Interview (MIDI): validation of a structured diagnostic clinical interview for impulse control disorders in an enriched community sample","volume":"265","author":"Chamberlain","year":"2018","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.eprac.2025.04.018_bib57","series-title":"The Oxford handbook of impulse control disorders","author":"Grant","year":"2011"},{"key":"10.1016\/j.eprac.2025.04.018_bib58","series-title":"The Oxford Handbook of Impulse control Disorders","article-title":"Assessment instruments for impulsivity and impulse control disorders","author":"Matusiewicz","year":"2011"},{"key":"10.1016\/j.eprac.2025.04.018_bib59","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1023\/A:1022119414440","article-title":"Exploring behavioral activation and inhibition sensitivities among college students at risk for bipolar spectrum symptomatology","volume":"21","author":"Meyer","year":"1999","journal-title":"J Psychopathology Behav Assess"},{"issue":"6","key":"10.1016\/j.eprac.2025.04.018_bib60","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1","article-title":"Factor structure of the Barratt impulsiveness scale","volume":"51","author":"Patton","year":"1995","journal-title":"J Clinical Psychology"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.018_bib61","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/mds.24023","article-title":"Questionnaire for impulsive-compulsive disorders in Parkinson's disease\u2013rating scale","volume":"27","author":"Weintraub","year":"2012","journal-title":"Movement Disorders"},{"issue":"1","key":"10.1016\/j.eprac.2025.04.018_bib62","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/10720162.2011.555709","article-title":"Reliability, validity, and psychometric development of the Hypersexual Behavior Inventory in an outpatient sample of men","volume":"18","author":"Reid","year":"2011","journal-title":"Sex Addict Compulsivity"},{"key":"10.1016\/j.eprac.2025.04.018_bib63","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1176\/ajp.144.9.1184","article-title":"The South Oaks Gambling Screen (SOGS): a new instrument for the identification of pathological gamblers","volume":"144","author":"Lesieur","year":"1987","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.eprac.2025.04.018_bib64","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1556\/JBA.1.2012.001","article-title":"Psychometric development of the hypersexual behavior consequences scale","volume":"1","author":"Reid","year":"2012","journal-title":"J Behav Addict"},{"issue":"3","key":"10.1016\/j.eprac.2025.04.018_bib65","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0376-6357(04)00140-8","article-title":"Measuring state changes in human delay discounting: an experiential discounting task","volume":"67","author":"Reynolds","year":"2004","journal-title":"Behav Processes"},{"issue":"2","key":"10.1016\/j.eprac.2025.04.018_bib66","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.neuroimage.2008.05.046","article-title":"Neural correlates of voluntary and involuntary risk taking in the human brain: an fMRI Study of the Balloon Analog Risk Task (BART)","volume":"42","author":"Rao","year":"2008","journal-title":"Neuroimage"},{"issue":"4","key":"10.1016\/j.eprac.2025.04.018_bib67","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1155\/2013\/579092","article-title":"The pathophysiology of impulse control disorders in Parkinson disease","volume":"26","author":"Balarajah","year":"2013","journal-title":"Behav Neurology"},{"issue":"1","key":"10.1016\/j.eprac.2025.04.018_bib68","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/EO-21-0038","article-title":"Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?","volume":"2","author":"De Sousa","year":"2022","journal-title":"Endocr Oncol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25001375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25001375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:21:08Z","timestamp":1778224868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X25001375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":68,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1530891X25001375"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2025.04.018","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impulse Control Disorders in Patients With Hyperprolactinemia on Dopamine Agonist Therapy\u2014How Concerned Should We Be?","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2025.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}